Lilly and Novo Bet on Amylin for Next-Generation Obesity Drugs Beyond GLP-1s

Two of the world's largest pharmaceutical companies are placing substantial bets on a new class of obesity medication, moving beyond the GLP-1 drugs that have dominated headlines and market share over the past few years. Eli Lilly and Novo Nordisk are both developing treatments built around amylin, a hormone that works through a different biological pathway than the GLP-1 medications currently prescribed to millions of patients seeking weight loss.

The shift reflects data emerging from late-stage clinical trials that suggest amylin-based drugs may offer a meaningful step forward in efficacy. Retatrutide, an experimental medication that targets amylin alongside other hormonal pathways, demonstrated weight loss of up to 25 percent in patients receiving the highest doses during Phase 3 testing. That result represents a notable benchmark—researchers and industry observers have characterized it as marking a new ceiling for what obesity medications can achieve in controlled trials.

The significance of this development lies partly in mechanism. GLP-1 drugs work by mimicking a naturally occurring hormone that regulates blood sugar and appetite. Amylin operates through a separate system, one that also influences satiety and metabolic function. By targeting amylin, pharmaceutical developers are essentially opening a different biological door, one that may produce weight loss through distinct pathways or potentially unlock additional health benefits beyond the scale. This distinction matters because it suggests the field is not simply iterating on existing approaches but genuinely expanding the toolkit.

Both Lilly and Novo Nordisk have already established themselves as major players in the obesity treatment space. Novo's Ozempic and Wegovy have become cultural touchstones, prescribed widely and discussed everywhere from medical conferences to social media. Lilly's tirzepatide, marketed as Zepbound, has emerged as a direct competitor. Yet the companies are not content to rest on these successes. The amylin opportunity represents a calculated wager that the next generation of treatments will command significant market share and potentially serve patients who do not respond adequately to current options.

The timing of these developments coincides with a broader scientific conversation about obesity treatment. Researchers and clinicians are increasingly viewing obesity as a chronic condition requiring sustained pharmaceutical intervention, much like diabetes or hypertension. That reframing has opened space for multiple drug classes to coexist and compete. It has also raised expectations about what new medications should accomplish—not merely weight reduction, but improvements in cardiovascular health, metabolic markers, and other outcomes that matter to patients and payers alike.

What remains to be seen is whether amylin-based drugs will translate their Phase 3 promise into real-world efficacy and whether they will find a durable place in clinical practice. The obesity drug market is crowded and growing, with multiple companies pursuing different biological targets. Regulatory approval, manufacturing scale, pricing, and insurance coverage will all shape whether retatrutide and similar compounds become standard options or remain niche alternatives. The companies betting on amylin are essentially wagering that the science is sound enough and the market large enough to justify the investment—and that patients and physicians will embrace a new generation of treatments even as the current one continues to expand.